INOMAX and Your Baby

INOMAX^® is a vasodilator, which, in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.

INOMAX Important Safety Information (ISI)
INOMAX should not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood

Read Full ISI

Parents

What Is INOMAX?

Approved by the FDA for treatment of term and near-term (>34 week) babies, INOMAX is an inhaled form of nitric oxide. INOMAX is used to relax the tiny blood vessels in the lungs. This allows more oxygen to move from the alveoli into the bloodstream. Studies have also shown that INOMAX significantly reduces the need for a more invasive proceedure called extracorporeal membrane oxygenation.⁷

How INOMAX Works

INOMAX is blended with oxygen in a ventilator. It works by relaxing tiny blood vessels surrounding the alveoli. When these vessels are too constricted (narrow), oxygen cannot move into the bloodstream. But as the vessels relax, blood flow to the lungs improves. This allows more oxygen to be picked up by the bloodstream, and improves oxygen levels in the baby's blood.

Risks and Side Effects

As with any treatment, the use of INOMAX, too, is associated with certain risks. In some cases, certain adverse effects can occur. These include:

Abnormally low blood pressure
Blood in the urine
Injury to lungs
High blood sugar
Infection/severe infection
Tissue inflamation
Reduced capacity for blood to carry oxygen
Elevated nitrogen dioxide⁹

Questions?

For more information about INOMAX, ask your healthcare professional.

You may also read our Full Prescribing Information located on this website.

References

5. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med. 1997;336:597-604.

7. INOMAX^® [package insert]. Clinton, NJ: Ikaria Holdings; 2009.

9. Data on file. Clinton, NJ: Ikaria^®; 2009.

The product information provided in this site is intended only for residents of the United States.
The product discussed herein may have different product labeling in different countries.

INOMAX Important Safety Information

INOMAX should not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood
Methemoglobinemia is a dose-dependent side effect of inhaled nitric oxide therapy. Therefore, methemoglobin levels should be monitored during INOMAX administration. Caution should be used when administering INOMAX with other drugs that can cause methemoglobinemia regardless of their route of administration
Nitrogen dioxide (NO₂) forms rapidly in gas mixtures containing nitric oxide and oxygen. NO₂ formed in this way can cause airway inflammation and damage
INOMAX must be administered through a system that does not cause excessive generation of NO₂ and that monitors for NO, NO₂, and FiO₂
Abrupt discontinuation of INOMAX therapy can lead to worsening of PaO₂ and increasing pulmonary artery pressure (PAP). Deterioration in oxygenation and elevation in PAP can also occur in children with no apparent response to INOMAX
In patients with pre-existing left ventricular dysfunction, inhaled nitric oxide may increase pulmonary capillary wedge pressure leading to pulmonary edema

Please see Full Prescribing Information.

Refer a Colleague to INOMAX^®

Disclaimer

*Please note: When you access these resources, you are leaving the INOMAX website. Therefore, INOMAX and Ikaria Holdings Inc. do not endorse the accuracy of the information you may find. We encourage you to talk to your doctor about the accuracy of any information you discover through these Internet resources.

Agree and continue →